Search results for "cancer genetics"

showing 10 items of 23 documents

Polymorphisms of an innate immune gene, toll-like receptor 4, and aggressive prostate cancer risk: a systematic review and meta-analysis.

2014

Background: Toll-like receptor 4 (TLR4) is one of the best known TLR members expressed on the surface of several leukocytes and tissue cells and has a key function in detecting pathogen and danger-associated molecular patterns. The role of TLR4 in the pathophysiology of several age-related diseases is also well recognized, such as prostate cancer (PCa). TLR4 polymorphisms have been related to PCa risk, but the relationship between TLR4 genotypes and aggressive PCa risk has not been evaluated by any systematic reviews. Methods: We performed a systematic review and meta-analysis of candidate-gene and genome-wide association studies analyzing this relationship and included only white populatio…

MaleProstate cancer polymorphisms of TLR4 aggressive prostate cancer risk meta-analysisSystematic Reviewslcsh:MedicineGenome-wide association studySingle-nucleotide polymorphismBiologyResearch and Analysis MethodsBioinformaticsPolymorphism Single NucleotideProstate cancerGenotypeGeneticsCancer GeneticsmedicineHumansSettore MED/05 - Patologia ClinicaGenetic Predisposition to DiseaseStatistical Methodslcsh:ScienceGenotypingGenetic associationEvolutionary BiologyMultidisciplinarylcsh:RProstatic NeoplasmsBiology and Life SciencesResearch Assessmentmedicine.diseaseImmunity InnateToll-Like Receptor 4Systematic reviewMeta-analysisPhysical SciencesGenetic Polymorphismlcsh:QPopulation GeneticsMathematicsStatistics (Mathematics)Genome-Wide Association StudyResearch ArticleMeta-AnalysisPLoS ONE
researchProduct

The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation.

2014

The Ewing sarcoma family of tumors (EFT) is a group of highly malignant small round blue cell tumors occurring in children and young adults. We report here the largest genomic survey to date of 101 EFT (65 tumors and 36 cell lines). Using a combination of whole genome sequencing and targeted sequencing approaches, we discover that EFT has a very low mutational burden (0.15 mutations/Mb) but frequent deleterious mutations in the cohesin complex subunit STAG2 (21.5% tumors, 44.4% cell lines), homozygous deletion of CDKN2A (13.8% and 50%) and mutations of TP53 (6.2% and 71.9%). We additionally note an increased prevalence of the BRCA2 K3326X polymorphism in EFT patient samples (7.3%) compared …

MaleCancer ResearchCell Cycle Proteinsmedicine.disease_causeFusion geneCDKN2AMedicine and Health Sciences2.1 Biological and endogenous factorsAetiologyChildGenetics (clinical)CancerPediatricMutationTissue microarrayTumorGenomeSarcomasHigh-Throughput Nucleotide SequencingAntigens NuclearSarcomaNeoplasm ProteinsOncologyChild PreschoolFemaleSarcomaResearch ArticleBiotechnologyHumanAdultPediatric Research Initiativelcsh:QH426-470Cohesin complexAdolescentPediatric CancerEwing SarcomaSarcoma EwingBiologyDisease-Free SurvivalFrameshift mutationCell LineGermline mutationRare DiseasesCell Line TumorEwingCancer GeneticsmedicineGeneticsHumansNuclearGenetic TestingAntigensPreschoolMolecular BiologyEcology Evolution Behavior and SystematicsGenome HumanHuman GenomeBiology and Life SciencesCancers and NeoplasmsInfantmedicine.diseaselcsh:GeneticsOrphan DrugMutationCancer researchGene DeletionDevelopmental Biology
researchProduct

Definition and management of colorectal polyposis not associated with APC/MUTYH germline pathogenic variants: AIFEG consensus statement

2021

An expert consensus panel convened by the Italian Association for Inherited and Familial Gastrointestinal Tumors (Associazione Italiana per lo Studio della Familiarita ed Ereditarieta dei Tumori Gastrointestinali, AIFEG) reviewed the literature and agreed on a number of position statements regarding the definition and management of polyposis coli without an identified pathogenic mutation on the APC or MUTYH genes, defined in the document as NAMP (non-APC/MUTYH polyposis).

Oncologymedicine.medical_specialtyGastrointestinal tumorsColorectal cancerSurgical ManagementColorectal polyposisGermline03 medical and health sciencesCancer Genetic0302 clinical medicineMUTYHInternal medicinemedicineCancer GeneticsPolyposis coliHepatologyPathogenic mutationbusiness.industryColorectal polyposis not associated with APC/MUTYH mutationPolyposis management guidelineGastroenterologyExpert consensusEndoscopic surveillancemedicine.diseaseColorectal cancerConsensus development conference030220 oncology & carcinogenesisCancer Genetics; Colorectal cancer; Colorectal polyposis not associated with APC/MUTYH mutation; Consensus development conference; Endoscopic surveillance; Polyposis management guideline; Surgical Management030211 gastroenterology & hepatologybusiness
researchProduct

Exome and immune cell score analyses reveal great variation within synchronous primary colorectal cancers

2019

BACKGROUND: Approximately 4% of colorectal cancer (CRC) patients have at least two simultaneous cancers in the colon. Due to the shared environment, these synchronous CRCs (SCRCs) provide a unique setting to study colorectal carcinogenesis. Understanding whether these tumours are genetically similar or distinct is essential when designing therapeutic approaches. METHODS: We performed exome sequencing of 47 primary cancers and corresponding normal samples from 23 patients. Additionally, we carried out a comprehensive mutational signature analysis to assess whether tumours had undergone similar mutational processes and the first immune cell score analysis (IS) of SCRC to analyse the interplay…

OncologyMaleCancer ResearchPROGNOSISCD3 ComplexColorectal cancerFEATURESmedicine.medical_treatmentDNA Mutational AnalysisCD8-Positive T-Lymphocytesmedicine.disease_causeTargeted therapyNeoplasms Multiple Primary0302 clinical medicineMUTATIONAL PROCESSESExomeLymphocytesExomeCancer geneticsExome sequencingAged 80 and overMutationMETHYLATIONMiddle Aged3. Good healthOncology030220 oncology & carcinogenesisDNA mismatch repairFemaleMicrosatellite InstabilityKRASColorectal Neoplasmsmedicine.medical_specialtyCARCINOMACD8 Antigens3122 Cancerscancer geneticscolorectal cancersuolistosyövätBiologyArticle03 medical and health sciencesCOLONInternal medicineKRASmedicineHumansSIGNATURESIMMUNOSCOREAgedDNA-analyysiMicrosatellite instabilitymedicine.diseaseColorectal cancerCase-Control StudiesMutationBritish Journal of Cancer
researchProduct

StellaTUM: current consensus and discussion on pancreatic stellate cell research

2011

The field of pancreatic stellate cell (PSC) biology is very young, as the essential in-vitro tools to study these cells (ie, methods to isolate and culture PSC) were only developed as recently as in 1998. Nonetheless, there has been an exponential increase in research output in this field over the past decade, with numerous research groups around the world focusing their energies into elucidating the biology and function of these cells. It is now well established that PSC are responsible for producing the stromal reaction (fibrosis) of two major diseases of the pancreas—chronic pancreatitis and pancreatic cancer. Despite exponentially increasing data, the methods for studying PSC remain var…

Liver CirrhosisPathologycell migrationpancreatic cancerCellpancreatitisPancreatic stellate cellLeading Articlehepatic surgerycell biologymolecular biologyhepatic fibrosis1506pancreaspancreatic surgerysignallinghepatic stellate cellalcoholPancreatic Stellate CellsGastroenterologypancreatic functionddc:medicine.anatomical_structurePancreaspancreatic fibrosissignal transductionstellate cellsmedicine.medical_specialtyStromal cellacute pancreatitisextracellular matrixadjuvant treatmentAbdominal surgerycancer geneticsliverpancreatic enzymesdigestive systemchronic pancreatitisstem cellsPancreatitis ChronicPancreatic cancermedicinecancerHumansRegenerationpancreatic physiologyendoscopyProgenitor cellmarkeradenocarcinomaHelicobacter pyloribusiness.industryfibrosisPancreatic Diseasesmedicine.diseaseexperimental pancreatitisLiver RegenerationPancreatic Neoplasmspancreatic pathologyconsensusCancer cellgene expressionHepatic stellate cellbusinesspancreatic diseaseGut
researchProduct

A Regulatory Mechanism Involving TBP-1/Tat-Binding Protein 1 and Akt/PKB in the Control of Cell Proliferation

2011

Abstract TBP-1 /Tat-Binding Protein 1 (also named Rpt-5, S6a or PSMC3) is a multifunctional protein, originally identified as a regulator of HIV-1-Tat mediated transcription. It is an AAA-ATPase component of the 19S regulative subunit of the proteasome and, as other members of this protein family, fulfils different cellular functions including proteolysis and transcriptional regulation. We and others reported that over expression of TBP-1 diminishes cell proliferation in different cellular contexts with mechanisms yet to be defined. Accordingly, we demonstrated that TBP-1 binds to and stabilizes the p14ARF oncosuppressor increasing its anti-oncogenic functions. However, TBP-1 restrains cell…

TBP-1/Tat-Binding Protein 1lcsh:Medicinemacromolecular substancesBiologymTORC2Cell GrowthTBP-1/Tat-Binding Protein 1; cell proliferationp14arfMolecular Cell BiologyGeneticsCancer GeneticsTranscriptional regulationGene Networkslcsh:ScienceBiologyProtein kinase BPI3K/AKT/mTOR pathwayMultidisciplinaryCell growthAKTBinding proteinlcsh:RMolecular biologySignaling CascadesCell biologyTBP-1enzymes and coenzymes (carbohydrates)cell proliferationbiology.proteinMdm2lcsh:QCell DivisionResearch ArticleSignal TransductionPLoS ONE
researchProduct

The retinoblastoma paradigm revisited

2008

Background: Retinoblastoma (Rb) is the most common primary malignant intraocular tumour in childhood. The "two hit" theory, formulated by Knudson in 1971 to explain the variegated clinical expression of the disease, led to the discovery of the so called tumour suppressor genes and the identification of the Rb1 as the prototype of such genes. Mutations of the Rb1 gene are now commonly believed to be the "cause" retinoblastoma, although epidemiological, clinical, and biological evidences argue against it. Material/Methods: The Authors have performed a systematic review of available data concerning clinical and diagnostic aspects of retinoblastoma, including molecular genetics. Meta analysis o…

Settore BIO/18 - GeneticaRetinoblastomacancer geneticsaneuploidyMutationAge FactorsRetinoblastomaHumansInfant
researchProduct

Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?

2021

Gastroenteropancreatic neuroendocrine neoplasia (GEPNEN) comprises clinically as well as prognostically diverse tumour entities often diagnosed at late stage. Current classification provides a uniform terminology and a Ki67-based grading system, thereby facilitating management. Advances in the study of genomic and epigenetic landscapes have amplified knowledge of tumour biology and enhanced identification of prognostic and potentially predictive treatment subgroups. Translation of this genomic and mechanistic biology into advanced GEPNEN management is limited. ‘Targeted’ treatments such as somatostatin analogues, peptide receptor radiotherapy, tyrosine kinase inhibitors and mammalian target…

0301 basic medicinemedicine.medical_treatmentcancer geneticsNeuroendocrine tumorsBioinformaticschemotherapyMolecular oncologyEpigenesis Genetic03 medical and health sciences0302 clinical medicinemolecular oncologyStomach NeoplasmsIntestinal NeoplasmsBiomarkers TumormedicineHumanscancer genetics; chemotherapy; immunotherapy; molecular oncology; neuroendocrine tumorsEpigeneticsPrecision Medicine610 Medicine & healthbusiness.industryGastroenterologyImmunotherapymedicine.diseasePancreatic NeoplasmsRadiation therapyClinical trial030104 developmental biologyTargeted drug delivery030220 oncology & carcinogenesis570 Life sciences; biologyIdentification (biology)immunotherapyneuroendocrine tumorsbusiness
researchProduct

BRCA1/2 molecular assay for ovarian cancer patients: A survey through Italian departments of oncology and molecular and genomic diagnostic laboratori…

2019

In Italy, 5200 new ovarian cancers were diagnosed in 2018, highlighting an increasing need to test women for BRCA1/2. The number of labs offering this test is continuously increasing. The aim of this study was to show the results coming from the intersociety survey coordinated by four different Clinical and Laboratory Italian Scientific Societies (AIOM, SIAPEC-IAP, SIBIOC, and SIGU). A multidisciplinary team belonging to the four scientific societies drew up two different questionnaires: One was targeted toward all Italian Departments of Medical Oncology, and the second toward laboratories of clinical molecular biology. This survey was implemented from September 2017 to March 2018. Seventy-…

0301 basic medicineOncologymedicine.medical_specialtyGenetic counselingClinical BiochemistrySomatic BRCAMultidisciplinary teamArticle03 medical and health sciences0302 clinical medicineInternal medicinePARP-1imedicine<i>brca1/2</i> assayslcsh:R5-920business.industryBRCA1/2 assaysBRCA1/2 assayOvary cancerTest (assessment)Laboratory test030104 developmental biologyMulticenter study030220 oncology & carcinogenesisCancer geneticsPretest posttestNGSlcsh:Medicine (General)businessBRCA1/2 assays; NGS; PARP-1i; Somatic BRCA
researchProduct

Vēža ģenētiskās testēšanas laboratorijas izveide Rīgā

2016

Onkoloģiskā saslimšana ir mūsdienās viena no smagākajām diagnozēm, no kuras ik gadu mirst liels cilvēku skaits pasaulē un Latvijā. Katru gadu pieaug pacientu skaits, kuriem ir diagnosticēts kāds no ļaundabīgā audzēja veidiem. Onkoloģijas pacienti ir visas pasaules mēroga problēma, un arī Latvijā vēža pacientu skaita pieaugums ir epidēmijas līmenī pašlaik. Diemžēl Latvijā ir novērojama tendence, ka vēzis tiek diagnosticēts vēlajās tā stadijās. Vēža diagnosticēšana tā agrākajā stadijā nozīmē pacienta dzīvildzes rādītāju pagarinājumu vai pat slimības remisiju. Vēža ģenētika sniedz visaptverošu informāciju par vēža slimības attīstību, tās iespējamajām lokācijām un daudzos gadījumos ar ģenētiskā…

VadībzinātneCancer genetic predisposition testingCancer genetic testingProjectCancer geneticsLaboratory
researchProduct